Clinical trials: Prostate-Specific Antigen, open to volunteers
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University
Prostate Cancer, Risk Assessment
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk…
- Conditions
- Prostate Cancer, Risk Assessment, Clinical Decision Support Systems, Predictive Value of Tests
- Trial name
- PROACT (NCT07733440)
- Testing
- (a) Training and (b) Supported risk assessment
- Where
- Nigeria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Ahmadu Bello University
PSMA-related Disease, Prostate Cancer
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer…
- Conditions
- PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690970
- Testing
- 68Ga/18F-PSMA/PSFA
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Prostate Carcinoma
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural…
- Trial name
- NCT06900348
- Testing
- PSA-Activated PSA-PAH1
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Suleyman Demirel University
Prostate CA
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer. The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people.
- Trial name
- TransPRIDE (NCT06987045)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Prostate Cancer
Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening
The project will investigate the efficacy of a Veteran-peer-navigator-led decision coaching (PDC) program to promote Shared Decision Making (SDM) for prostate cancer screening among Veterans at the Veterans Health Administration…
- Trial name
- NCT06549036
- Testing
- Veteran Peer Decision Coaching Session for PSA Screening
- Where
- United States
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development